Brokerages Set ABIVAX Société Anonyme (NASDAQ:ABVX) PT at $38.67

ABIVAX Société Anonyme (NASDAQ:ABVX) has been given a consensus rating of “Buy” by the seven analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $38.67.

ABVX has been the subject of a number of analyst reports. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. JMP Securities reiterated a “market outperform” rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th.

ABIVAX Société Anonyme Stock Up 0.2 %

ABIVAX Société Anonyme stock opened at $6.09 on Thursday. ABIVAX Société Anonyme has a twelve month low of $5.54 and a twelve month high of $17.02. The stock’s fifty day simple moving average is $7.57 and its 200-day simple moving average is $9.96.

Institutional Trading of ABIVAX Société Anonyme

A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC acquired a new position in shares of ABIVAX Société Anonyme in the 4th quarter valued at $29,000. R Squared Ltd acquired a new position in shares of ABIVAX Société Anonyme in the 4th quarter valued at $36,000. BNP Paribas Financial Markets boosted its holdings in shares of ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the last quarter. Walleye Capital LLC boosted its holdings in shares of ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares during the last quarter. Finally, abrdn plc boosted its holdings in shares of ABIVAX Société Anonyme by 34.1% in the 4th quarter. abrdn plc now owns 424,181 shares of the company’s stock valued at $3,105,000 after purchasing an additional 107,750 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.